Many materials in confidential biopharm waste are similar to other industries but the mix of hazardous and non-hazardous substances creates a challenge for recycling service providers.
By separating these materials at source service providers can cut “ever increasing” landfill costs, Lucy Russell, security shredding manager at Smurfit Kappa Recycling, told Outsourcing-Pharma.
Pharmaceutical companies must be careful when choosing a recycling partner. Equally, they can ill-afford for “confidential materials to be put into their general waste and to be found on a local rubbish tip”, said Russell.